

Publication about the scAb-AID2 technology as a collaboration with National Institute of Genetics

Kanagawa, Japan - FIMECS, Inc. ("FIMECS"), a private biotechnology company creating a new class of drugs based on protein degradation, today announces that the results of research collaboration with National Institute of Genetics has been published in Journal of Cell Science on July 5, 2025.

Title: A single-chain antibody-based AID2 system for conditional degradation of GFP-tagged and untagged proteins

Authors: Moutushi Islam, Takefumi Negishi, Naomi Kitamoto*, Yuki Hatoyama, Kanae Gamo*, Ken-ichiro Hayashi, Masato T. Kanemaki (*Member of FIMECS)

Journal of Cell Science, 138 (13): jcs263961, 2025

In collaboration with Prof. Kanemaki, a professor at National Institute of Genetics, FIMECS has been working to apply the auxin-inducible degron (AID) technology to in vivo animal models. In this study, we further advanced the improved AID2 technology and developed a new system called scAb-AID2 (single-chain antibody AID2), which enables the degradation of target proteins without the need for genetic tagging. FIMECS contributed to the in vivo validation of scAb-AID2 using mouse models, demonstrating that degradation of target proteins can affect biological functions. This result highlights the potential of AID2 technology for therapeutic applications.

"FIMECS contributed to the validation of scAb-AID2 in vivo using mouse models, demonstrating that degradation of target proteins can affect biological functions. This result highlights the potential of AID2 technology for therapeutic applications." said Katsuhiro Uto, CEO of FIMECS. "The results pave the way for broader application of AID2-based target depletion in both model and non-model organisms. By combining this technology with our proprietary RaPPIDS™ platform, we will further accelerate the development of innovative therapeutics."

For More Information: [A new technology that enables degradation of target proteins without fusing a degron tag.:National Institute of Genetics](#)

About FIMECS, Inc.

FIMECS, Inc. is developing a new class of drugs based on targeted protein degradation for the currently 'undruggable' targets in immuno-oncology and oncology areas. The company became able to discover drug candidates for inducing the degradation of disease-relevant targeted proteins by integrating proprietary E3 ligase binders and RaPPIDS™ platform. This drug discovery platform will help providing drugs to the patients all over the world through various internal and collaboration projects. <https://www.fimecs.com/eng/>

About AID2 technology:

The technology enables the rapid and inducible degradation of AID-tagged target proteins in mammalian cells and mice by the addition of a small ligand that is an analog of the plant hormone auxin.

#

Contact:

FIMECS, Inc.

26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan

TEL: +81-466-96-0261

E-mail: info@fimecs.com